Roche and Novartis continue fight against Italian fine despite court setback
This article was originally published in SRA
Executive Summary
Roche and Novartis say they will continue to fight against the fine imposed on them earlier this year for allegedly colluding to exclude Roche's Avastin from the ophthalmology market in favor of Novartis's much more expensive Lucentis, despite losing their first challenge in the Italian courts1,2.